Tirzepatide linked to more GI issues than semaglutide in new study on weight-loss drugs without diabetes. Read more!

Tirzepatide is the active ingredient in Zepbound, approved by the Food and Drug Administration (FDA) specifically for weight loss. Semaglutide was initially approved under the brand name Ozempic ...

INDIANAPOLIS – The way people are accessing GLP-1 medications Semaglutide and Tirzepatide is going to become very limited after the drugs were taken off the FDA’s shortage list.

Tirzepatide may be more effective than semaglutide or liraglutide for weight loss, as it has a dual mechanism of action.

Prescribing of drugs between 2021 and 2023 shifted dramatically for both type 2 diabetes and weight loss for people with ...

Tirzepatide was associated with better glycemic control and weight loss outcomes than semaglutide and insulin among patients with T2D.

After approval, tirzepatide dispensations increased markedly among adults with type 2 diabetes prescribed glucose-lowering ...

"With the FDA announcing the resolution of shortages for Semaglutide (Wegovy, Ozempic) and Tirzepatide (Zepbound, Mounjaro), compounding pharmacies must halt production of these medications. This ...

Dispensations of tirzepatide and semaglutide increased significantly in recent years while the use of other glucose-lowering and weight-lowering therapies declined, an analysis showed. The ...

Among all antiobesity medications, the incremental cost-effectiveness ratios were $197,023 and $467,676 per quality-adjusted life-year for tirzepatide and semaglutide, respectively. HealthDay News ...